Cubist Systematic Strategies, LLC Apellis Pharmaceuticals, Inc. Call Options Transaction History

Cubist Systematic Strategies, LLC

  • $15.8 Billion
  • Q3 2024

Call Options

5 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q2 2024

Aug 14, 2024
SELL
$38.07 - $59.71 $392,121 - $615,013
-10,300 Reduced 40.87%
14,900 $571,000
Q1 2024

May 15, 2024
BUY
$55.39 - $72.47 $997,020 - $1.3 Million
18,000 Added 250.0%
25,200 $1.48 Million
Q4 2023

Feb 14, 2024
BUY
$37.14 - $64.82 $33,426 - $58,337
900 Added 14.29%
7,200 $430,000
Q2 2023

Aug 14, 2023
BUY
$76.68 - $93.31 $130,356 - $158,627
1,700 Added 36.96%
6,300 $573,000
Q1 2023

May 15, 2023
BUY
$46.59 - $66.96 $214,314 - $308,016
4,600 New
4,600 $303,000

Others Institutions Holding APLS

# of Institutions
308
Shares Held
115M
Call Options Held
3.85M
Put Options Held
1.09M
View Full List

About Apellis Pharmaceuticals, Inc.

APLS Quotes by TradingView
  • Ticker APLS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 109,865,000
  • Market Cap $3.64B
  • Description
  • Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...
More about APLS
Track This Portfolio

Track Cubist Systematic Strategies, LLC Portfolio

Follow Cubist Systematic Strategies, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cubist Systematic Strategies, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cubist Systematic Strategies, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email